Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Pharmaceutics|February 26, 2022
Oligonucleotide Therapeutics: From Discovery and Development to PatentabilityLara Moumné, Anne-Céline Marie, Nicolas Crouvezier
Frontiers in Neurology|October 30, 2013
Multiple Aspects of Gene Dysregulation in Huntington's DiseaseLara Moumné, Sandrine Betuing, Jocelyne Caboche
Medecine Sciences : M/S|February 17, 2023
[Mechanisms of action and patentability of therapeutic oligonucleotides]Nicolas Crouvezier, Anne-Céline Marie, Lara Moumné
Human Molecular Genetics|October 13, 2005
Deletions in the polyAlanine-containing transcription factor FOXL2 lead to intranuclear aggregationLara Moumné, Marc Fellous, Reiner A Veitia
Plos One|February 21, 2012
Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's diseaseLara Moumné, Ken Campbell, David Howland, et al.
Human Mutation|May 20, 2008
Differential functional effects of novel mutations of the transcription factor FOXL2 in BPES patientsJeyabalan Nallathambi, Paul Laissue, Frank Batista, et al.
Pageof 2